Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Open accessAbstract
Background: The metabolic syndrome (MS) is often accompanied by atherogenic dyslipidemia, which is characterized by elevated triglycerides (TG), reduced high‐density lipoprotein cholesterol (HDL‐C), and elevated numbers of small, dense low‐density lipoprotein(LDL) particles. Hypothesis: It was hypothesized that a threshold exists for the circulating TG level needed to produce changes in LDL subclass distribution. Methods: Hypertriglyceridemic (TG ≥300 and <1000 mg/dl) subjects with the MS were randomly assigned to placebo (n= 50) or 130 mg/day of micronized fenofibrate‐coated microgranules (n = 96) for 8 weeks. Results: In the overall analysis, fenofibrate treatment resulted in significant (p<0.05) changes versus placebo in TG (‐36.6%), non‐HDL‐C (−7.5%), very low‐density lipoprotein‐C (−32.7%), LDL‐C (15.0%), HDL‐C (14.0%), remnant lipoprotein‐C (−35.1%), apolipoprotein B (−6.0%), apoli‐poprotein A‐I (5.3%), and apolipoprotein C‐III −29.7%). Changes in LDL particle diameter in the fenofibrate group were significantly inversely associated with the TG level achieved on treatment (p = 0.019). When individually matched for percent change in TG, subjects with on‐treatment TG < 200 mg/dl, in contrast to those with on‐treatment values ≥200 mg/dl, had significantly different median responses (p < 0.05) in LDL size (0.79 vs. −0.06 nm) and cholesterol carried by small (−35 vs. 21 mg/dl) and large (31 vs. 11 mg/dl) particles. Conclusion: These data support the view that a threshold exists below which the TG level must be lowered to produce shifts in LDL particle size.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fenofibrate treatment typically reduces serum triglycerides by a mean change of −93.7 mg/dL (−39.3%), increases high density lipoprotein cholesterol by +5.5 mg/dL (+12.4%), and reduces low density lipoprotein cholesterol by −17.9 mg/dL (−12.3%).
“Typical changes in serum lipids as a result of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of −93.7 mg/dL (−39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by −17.9 mg/dL (−12.3%).”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [38]
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · see citing works
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · see citing works
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · see citing works
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237 · see citing works
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139 · see citing works
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94 · see citing works
Self-citationMaki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · see citing works
Self-citationMaki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.09.001 · Cited by 81 · see citing works
Self-citationDavidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.08.001 · Cited by 71 · see citing works
Self-citationDunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52 · see citing works
Self-citationFenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works
“4%) for HDLC [32-44] (see Fig.”
Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181b0cf71 · Cited by 32 · see citing works
Self-citation
- Authors
- Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R.
- Affiliations
- Rush University Medical Center (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Radiant Research (United States) (US)
- Corresponding author
- Davidson, Michael H.
- Venue
- Clinical Cardiology
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 29
- Issue
- 6
- Pages
- 268-273
- ISSN
- 0160-9289 (ISSN-L)
- 1932-8737
- PMC
- PMC6653967
- OpenAlex
- W1970736991
- Cited by
- 51
- References
- 3
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cardiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- fenofibrate, atherogenic dyslipidemia, hypertriglyceridemia, metabolic syndrome, LDL particle size, small dense LDL, HDL cholesterol, remnant lipoproteins, apolipoprotein C-III, apolipoprotein B, apolipoprotein A-I, VLDL, non-HDL cholesterol
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Double-Blind Method, Female, Humans, Lipids, Cholesterol, LDL, Male, Middle Aged, Particle Size, Fenofibrate, Hypertriglyceridemia, Metabolic Syndrome, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
